

The Case for Intravenous Arginine Stimulation In Lieu of Mixed-Meal Tolerance Tests as Outcome Measure for Intervention Studies in Recent-Onset Type 1 Diabetes

CARLA GREENBAUM, MD¹
KRISTY SEIDEL, MS²
CATHERINE PIHOKER, MD³

Residual β -cell function in patients with type 1 diabetes has been generally determined by C-peptide response to stimulation by a liquid mixed-meal tolerance test (MMTT) or intravenous glucagon (1). Early trials assessed benefits of therapy by frequency and duration of the clinical remission phase in which minimal or no exogenous insulin was needed to maintain euglycemia (reviewed in 2). What is now needed is the most sensitive, and not necessarily the most physiologic measure, so that any improvement in β -cell function during a clinical trial can be detected. Both the MMTT and the intravenous glucagon test have practical limitations. The MMTT takes 2–4 h to complete, and the stimulus is subject to variations in gastrointestinal absorption, while the intravenous glucagon test often invokes nausea.

In contrast, the use of intravenous arginine to stimulate and measure β -cell secretion takes only a few minutes to perform, circumvents gastrointestinal variation, and is clinically well tolerated. In addition, responses to this nonglucose secretagogue have been demonstrated to persist after the diagnosis of diabetes at a time when responses to glucose are gone (3–6). Our goal was to determine whether arginine-stimulated C-peptide could be used in lieu of MMTT as an out-

come measure for intervention studies in recent-onset type 1 diabetes.

RESEARCH DESIGN AND METHODS

— Institutional review board approval and informed consent were obtained before the study began. Nineteen subjects between 7–42 and 1–24 months postdiagnosis of type 1 diabetes came to the Clinical Research Center after an overnight fast. Morning insulin was withheld. Subjects on insulin pumps continued their basal rate until the start of the test. Tests were not performed if fasting glucose was ≤ 4.0 or ≥ 11 mmol/l. Subjects underwent paired MMTT (baseline samples, oral Boost [6 mg/kg to maximum of 360 ml], samples at 30, 60, 90, and 120 min) and arginine testing (baseline samples, intravenous arginine [0.07 mg/kg to maximum of 5 g], samples at 2, 3, 5, 7, and 10 min) on separate days within 4 weeks of each other.

RESULTS — There was no difference in basal C-peptide (1.0 ± 0.3 nmol/l for MMTT and 1.1 ± 0.3 nmol/l for arginine [mean \pm SE]) or glucose (7.3 ± 0.6 mmol/l for MMTT and 7.7 ± 0.4 mmol/l for arginine) values. Likewise, there was no difference in mean or peak C-peptide values between MMTT and arginine-stimulated tests. There was a strong rela-

tionship between C-peptide values obtained from MMTT and arginine-stimulated tests whether assessed by mean ($r = 0.96$), peak ($r = 0.95$), or area under the curve ($r = 0.95$) calculations. In addition, a strong relationship between basal and stimulated C-peptide values was observed for both MMTT and arginine.

Glucose values poststimulation were markedly higher in the MMTT (peak 14.8 ± 0.9 mmol/l for MMTT and 7.9 ± 0.4 mmol/l for arginine). There was no relationship between basal glucose values and stimulated C-peptide results for arginine, whereas a weak relationship was seen for MMTT ($r = -0.31$ between basal glucose and mean C-peptide). A strong inverse relationship between time to peak on MMTT and arginine-stimulated C-peptide responses was seen (Fig. 1).

CONCLUSIONS — This study demonstrates that C-peptide stimulation with an intravenous arginine bolus in recently diagnosed patients with type 1 diabetes provides a similar measure of residual β -cell function to that of MMTT. In addition, the arginine test is easier to perform and better tolerated since it requires only a short time and does not result in hyperglycemia.

This study also demonstrates no impact of basal glucose level on C-peptide values poststimulation during arginine treatment. Investigators have often noted that one characteristic of mildly abnormal β -cell function is an apparent delay in the peak of C-peptide secretion to oral stimulation whether by oral glucose or a liquid mixed meal. We observed a strong inverse relationship between time to peak on MMTT and C-peptide responses to arginine. These data suggest that the amplitude of C-peptide response to arginine can be used in place of a time delay to peak value on MMTT.

Our data also provide somewhat reassuring information about the reproduc-

From the ¹Benaroya Research Institute, Diabetes Clinical Research, Seattle, Washington; the ²Children's Hospital and Regional Medical Center, Clinical Research Center and Research Administration, Seattle, Washington; and the ³Department of Pediatrics, University of Washington, Seattle, Washington.

Address correspondence and reprint requests to Carla Greenbaum, Benaroya Research Institute, 1201 9th Ave., Seattle, WA 98101. E-mail: cjgreen@benaroyaresearch.org.

Received for publication 13 November 2003 and accepted in revised form 19 January 2004.

Abbreviations: MMTT, mixed-meal tolerance test.

© 2004 by the American Diabetes Association.




Figure 1—Relationship between time to peak C-peptide value on MMTT and arginine (ARG)-stimulated peak C-peptide responses ($r = -0.93$) ($n = 10$).

ibility of β -cell function testing. There was remarkable concordance in results between β -cell function tests performed up to 4 weeks apart. In addition, the mean percentage difference between C-peptide values obtained poststimulation with arginine compared with MMTT was $\sim 12\%$, which was about the same as the mean difference in the basal C-peptide levels obtained on different days and is similar to reproducibility noted for other measures of β -cell function (7).

The choice of what measure to use to assess β -cell function depends on the question. The MMTT was originally developed to mimic the activity of the β -cell under real-life conditions (in response to a meal with multiple dietary components). However, a goal of current clinical trials in subjects newly diagnosed with type 1 diabetes is to determine whether intervention therapies have any effect on β -cell function. Such a test should have minimal impact on participants and should provide a reproducible and sensitive measure of the health of the β -cell. The arginine test clearly meets these requirements. Several investigations have suggested that the β -cell response to arginine correlates with β -cell mass. Ryan et al. (8) have recently reported a close relationship between the number of islet equivalents transplanted and the insulin response to intravenous arginine. Similarly, changes in the glucose-potentiated arginine response have been shown to correlate with islet mass in a baboon model of diabetes (9). Several studies

have now shown that responses to arginine correlate with clinical status (i.e., remission), whether tested during a clinical trial (10) or natural history studies (5,11–15).

In conclusion, the arginine-stimulated test provides similar data as the MMTT, prevents hyperglycemia, and is better tolerated by subjects than the MMTT. Thus, this test should be considered as an alternative end point in clinical trials aimed at preserving β -cell function.

Acknowledgments—This study was supported by the Juvenile Diabetes Research Foundation Center for Translational Research grant awarded to the Benaroya Research Institute and the Clinical Research Center of the Children's Hospital and Regional Medical Center. Some of these studies were conducted at the University of Washington's Pediatric Clinical Research Center (N01RR00037) and used the resources of the University of Washington's Diabetes Endocrinology Research Center (DK17047). C.J.G. is also supported in part by grants from the Paul G. Allen Foundation Clinical Scholars Program and the Buse Diabetes Clinical Research Chair.

The authors thank the research participants and their families and the nurses of the Clinical Research Center of the Children's Hospital and Regional Medical Center and the Benaroya Research Institute. Elizabeth Langeland, Kristy Meyer, Daxa Sabahya, Marli McCulloch-Olson, and Ami Davy served as clinical coordinators on this study. This study used the Benaroya Research Institute clinical database developed by Bert Park.

References

1. Faber OK, Binder C: C-peptide response to glucagon: a test for the residual β -cell function in diabetes mellitus. *Diabetes* 26:605–610, 1977
2. Greenbaum CJ: Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials. *Clin Immunol* 104:97–104, 2002
3. Bardet S, Rohmer V, Daugendre D, Marre M, Semana G, Limal JM, Allanic H, Charbonnel B, Sai P: Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 34:648–654, 1991
4. Chaillous L, Rohmer V, Maugeudre D, Lecomte P, Marechaud R, Marre M, Guilhem I, Charbonnel B, Sai P: Differential β -cell response to glucose, glucagon, and arginine during progression to type 1 (insulin-dependent) diabetes mellitus. *Metabolism* 45:306–314, 1996
5. Heinze E, Beischer W, Keller L, Winkler G, Teller WM, Pfeiffer EF: C-peptide secretion during the remission phase of juvenile diabetes. *Diabetes* 27:670–676, 1978
6. Savage PJ, Bennion LJ, Flock EV, Bennett PH: Beta cell dysfunction in maturity-onset diabetes: reversible loss of glucose-induced insulin secretion with retention of response to arginine. *Adv Exp Med Biol* 119:219–225, 1979
7. Arnold-Larsen S, Madsbad S, Kuhl C: Reproducibility of the glucagon test. *Diabet Med* 4:299–303, 1987
8. Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte RV, Shapiro AM: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. *Di-*

- abetes 51:2148–2157, 2002
9. McCulloch DK, Koerker DJ, Kahn SE, Bonner-Weir S, Palmer JP: Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons. *Diabetes* 40:673–679, 1991
10. Dupre J, Jenner MR, Mahon JL, Purdon C, Rodger NW, Stiller CR: Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine. *Diabetes* 40:598–604, 1991
11. Ganda OP, Srikanta S, Brink SJ, Morris MA, Gleason RE, Soeldner JS, Eisenbarth GS: Differential sensitivity to beta-cell secretagogues in “early,” type 1 diabetes mellitus. *Diabetes* 33:516–521, 1984
12. Giugliano D, Luyckx AS, Lefebvre PJ: Plasma C-peptide response to arginine in insulin-dependent diabetic subjects. *J Endocrinol Invest* 3:19–23, 1980
13. Menchini M, Meschi F, Lambiase R, Puzovio M, Del Guercio MJ, Chiumello G: C-peptide response to arginine stimulation in diabetic children. *J Pediatr* 96:362–366, 1980
14. Reynolds C, Molnar GD, Horwitz DL, Rubenstein AH, Taylor WF, Jiang NS: Abnormalities of endogenous glucagon and insulin in unstable diabetes. *Diabetes* 26:36–45, 1977
15. Vetter U, Heinze E, Thon A, Beischer W, Teller W: The effect of glucose, tolbutamide, and arginine on C-peptide release during remission in type 1 diabetes mellitus. *Eur J Pediatr* 140:305–310, 1983